iRhythm Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
14analysts covering
FY Revenue (est.)
$886.4Mnext fiscal year
FY EPS (est.)
$0.58next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly199.4MTarget: 875000000 to 885000000 (Full Year 2026)
Gross Margin Quarterly7,090.0%Target: Incremental improvement for full-year 2026
Adjusted EBITDA Margin Quarterly710.0%Target: 12% to 13% (Full Year 2026)
Watch Items
- Zio MCT FDA Approval and Commercial LaunchTrigger: FDA 510(k) clearance or further regulatory delaysAction: Monitor regulatory filings and management updates regarding the commercial implementation timeline aligned to 2027.
- DOJ Subpoena and Shareholder InvestigationsTrigger: Resolution of active shareholder investigations or updates on DOJ subpoenaAction: Assess potential financial liabilities, legal expenses, and impacts on corporate reputation.
Research as of 19 Jun 2026